SFS
CRSP icon

Sowell Financial Services’s CRISPR Therapeutics CRSP Stock Holding History

Sowell Financial Services’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-3,558
Closed -$231K – 1123
2025
Q3 		$231K Buy
+3,558
New +$204K 0.01% 935
2025
Q2 		– Sell
-11,554
Closed -$393K – 1050
2025
Q1 		$393K Buy
11,554
+900
+8% +$38.2K 0.02% 659
2024
Q4 		$419K Buy
+10,654
New +$503K 0.02% 428
2021
Q2 		– Sell
-715
Closed -$77K – 976
2021
Q1 		$77K Buy
715
+162
+29% +$24.5K ﹤0.01% 1484
2020
Q4 		$85K Buy
553
+61
+12% +$7.21K ﹤0.01% 1212
2020
Q3 		$41K Buy
492
+120
+32% +$10.6K ﹤0.01% 1283
2020
Q2 		$27K Buy
372
+67
+22% +$3.92K ﹤0.01% 1359
2020
Q1 		$13K Buy
305
+195
+177% +$10.1K ﹤0.01% 1520
2019
Q4 		$7K Buy
110
+60
+120% +$3.28K ﹤0.01% 1795
2019
Q3 		$2K Buy
+50
New +$2.39K ﹤0.01% 2049

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
GP
GSK plc London $602M AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Sowell Financial Services's CRSP Position: Q4 2025 in Review

Sowell Financial Services sold out of CRISPR Therapeutics (CRSP) in Q4 2025, closing a stake of 3,558 shares — an estimated $231K sold.

Sowell Financial Services first reported a position in CRSP in Q3 2019 and held it in 10 quarters. The position peaked at $419K in Q4 2024. 479 funds tracked by Wall St. Rank hold CRSP as of Q4 2025.

  • Sowell Financial Services reported no remaining CRISPR Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Sowell Financial Services sold 3,558 CRISPR Therapeutics shares in Q4 2025, an estimated $231K.
  • Sowell Financial Services first reported a position in CRISPR Therapeutics in Q3 2019 and held it in 10 quarters.
  • Sowell Financial Services's CRISPR Therapeutics position peaked at $419K in Q4 2024.
  • 479 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2025.

Based on Sowell Financial Services's 13F filing for Q4 2025, filed 21 Jan 2026.